← Back to Clinical Trials
Recruiting NCT03976999

NCT03976999 Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03976999
Status Recruiting
Phase
Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Condition Carcinoma, Ovarian Epithelial
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2017-07-05
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Biological collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2017-07-05 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.

Eligibility Criteria

Inclusion Criteria: * 18 or older * Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer * Patient eligible for, at least, one surgery and a chemotherapy * Patient having given his informed, written and express consent Exclusion Criteria: * Patient not affiliated to a social protection scheme * Pregnant and / or nursing women * Subject under tutelage, curatorship or safeguard of justice * Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons

Contact & Investigator

Central Contact

Aurore MOUSSION

✉ DRCI-icm105@icm.unicancer.fr

📞 +33 4 67 61 31 02

Principal Investigator

COLOMBO Pierre-Emmanuel, M.D

PRINCIPAL INVESTIGATOR

ICM - Institut régional du Cancer Montpellier

Frequently Asked Questions

Who can join the NCT03976999 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Carcinoma, Ovarian Epithelial. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03976999 currently recruiting?

Yes, NCT03976999 is actively recruiting participants. Contact the research team at DRCI-icm105@icm.unicancer.fr for enrollment information.

Where is the NCT03976999 trial being conducted?

This trial is being conducted at Montpellier, France.

Who is sponsoring the NCT03976999 clinical trial?

NCT03976999 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is COLOMBO Pierre-Emmanuel, M.D at ICM - Institut régional du Cancer Montpellier. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology